<DOC>
	<DOCNO>NCT00702156</DOCNO>
	<brief_summary>The principal research objective demonstrate cardioselective beta-blockade use bisoprolol inferior placebo regard pulmonary function improve quality life patient heart failure coexistent moderate severe chronic obstructive pulmonary disease without significant reversibility . Patients follow 4 month bisoprolol up-titrated maximum clinically tolerate dose . Health status assess use generic two disease specific questionnaire , pulmonary function spirometry , body box plethysmography , cardiopulmonary exercise testing .</brief_summary>
	<brief_title>Bisoprolol Patients With Heart Failure Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>symptomatic NYHA II III chronic heart failure leave ventricular systolic dysfunction moderate severe chronic obstructive pulmonary disease without significant reversibility beta−blocker contraindication non−dihydropyridine ( diltiazem / verapamil ) calcium channel blocker recent coronary percutaneous intervention coronary artery bypass graft surgery haemodynamically significant valvular disease hypertrophic cardiomyopathy . active myocarditis pericarditis . recent cerebrovascular accident transient ischaemic attack serious concurrent systemic disease , malignancy , result likely reduce life expectancy pregnancy , childbearing potential inadequate contraception , breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Beta-blockers</keyword>
	<keyword>Pulmonary Function</keyword>
</DOC>